ESRRA and breast carcinoma: Deblois et al. also showed that pharmacological inhibition of ERRα activity in a breast cancer cell line resistant to epidermal growth factor receptor inhibition by the anti-cancer drug lapatinib leads to reduced detoxification capacity and increased oxidative damage [11].